J Genomics 2018; 6:103-112. doi:10.7150/jgen.20581

Research Paper

Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma

Suriya Narayanan Murugesan1*, Birendra Singh Yadav1*, Pramod Kumar Maurya1*, Amit Chaudhary1*, Swati Singh2*, Ashutosh Mani1*✉

1. Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India-211004.
2. Center of Bioinformatics, University of Allahabad, India-211002.
*All authors contributed equally.


Y-Box Binding protein 1 (YBX-1) is known to be involved in various types of cancers. It's interactors also play major role in various cellular functions. Present work aimed to study the expression profile of the YBX-1 interactors during lung adenocarcinoma (LUAD). The differential expression analysis involved 57 genes from 95 lung adenocarcinoma samples, construction of gene network and topology analysis. A Total of 43 genes were found to be differentially expressed from which 17 genes were found to be down regulated and 26 genes were up-regulated. We observed that Polyadenylate-binding protein 1 (PABPC1), a protein involved in YBX1 translation, is highly correlated with YBX1. The interaction network analysis for a differentially expressed non-coding RNA Growth Arrest Specific 5 (GAS5) suggests that two proteins namely, Growth Arrest Specific 2 (GAS2) and Peripheral myelin protein 22 (PMP22) are potentially involved in LUAD progression. The network analysis and differential expression suggests that Collagen type 1 alpha 2 (COL1A2) can be potential biomarker and target for LUAD.

Keywords: YBX1, regulatory network, lung adenocarcinoma, RNA-Seq.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Murugesan SN, Yadav BS, Maurya PK, Chaudhary A, Singh S, Mani A. Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma. J Genomics 2018; 6:103-112. doi:10.7150/jgen.20581. Available from http://www.jgenomics.com/v06p0103.htm